KRAS and neoplasm: Analysis of 151 cSCC tumour samples curated in Cbioportal34,35 indicated TP53 mutations in 76%, NOTCH1 in 55%, TGFBR1 in 6%, TGFBR2 in 8% and mutation of KRAS, HRAS and NRAS combined occurred in 17.6% of samples (Supplementary Fig. 13).